Harvard Apparatus Regenerative Technology Inc. (HRGN)
| Market Cap | 39.96M +17.0% |
| Revenue (ttm) | 982.00K +44.6% |
| Net Income | -6.68M |
| EPS | -0.39 |
| Shares Out | 20.28M |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 7,061 |
| Open | 2.000 |
| Previous Close | 1.973 |
| Day's Range | 1.970 - 2.000 |
| 52-Week Range | 0.960 - 2.463 |
| Beta | -0.28 |
| Analysts | n/a |
| Price Target | n/a |
| Est. Earnings | Nov 9, 2026 |
About HRGN
Harvard Apparatus Regenerative Technology Inc., a clinical-stage biotechnology company, focuses on developing regenerative-medicine treatments for disorders of the gastro-intestinal system and other organs resulting from cancer, trauma, or birth defects. The company’s lead product candidate is Cellspan Esophageal Implant for the treatment of severe esophageal disease. It’s pipeline includes organ-regeneration technology for the repair or replacement of diseased or damaged organs; and product candidates to treat conditions of the esophagus, incl... [Read more]
Financial Performance
In 2025, HRGN's revenue was $704,000, an increase of 63.72% compared to the previous year's $430,000. Losses were -$6.87 million, -11.16% less than in 2024.
Financial StatementsNews
Harvard Apparatus Regenerative Technology Quarterly report: Q2 2026
Harvard Apparatus Regenerative Technology has published its Q2 2026 quarterly earnings report on August 13, 2026.
Harvard Apparatus Regenerative Technology Quarterly report: Q1 2026
Harvard Apparatus Regenerative Technology has published its Q1 2026 quarterly earnings report on May 13, 2026.
Harvard Apparatus Regenerative Technology Announces First Patient Treated with Cellspan Esophageal Implant at Mayo Clinic
Holliston, Mass., April 27, 2026 (GLOBE NEWSWIRE) -- Harvard Apparatus Regenerative Technology, Inc. (OTCQB: HRGN) (“Harvard Apparatus Regenerative Technology” or the “Company”), a clinical-stage biot...
Harvard Apparatus Regenerative Technology Proxy statement: Proxy filing
Harvard Apparatus Regenerative Technology filed a proxy statement on April 23, 2026, providing details for shareholder voting and corporate governance matters.
Harvard Apparatus Regenerative Technology Annual report: Q4 2025
Harvard Apparatus Regenerative Technology has published its Q4 2025 annual report on March 19, 2026.
Harvard Apparatus Regenerative Technology Collaborates with University of Southern California to Test Treatment for Esophageal Disease
HOLLISTON, Mass., Jan. 21, 2026 (GLOBE NEWSWIRE) -- Harvard Apparatus Regenerative Technology, Inc. (OTCQB: HRGN) (“Harvard Apparatus Regenerative Technology” or the “Company”), a clinical-stage biote...
Harvard Apparatus Regenerative Technology Quarterly report: Q3 2025
Harvard Apparatus Regenerative Technology has published its Q3 2025 quarterly earnings report on November 7, 2025.
Harvard Apparatus Regenerative Technology Quarterly report: Q2 2025
Harvard Apparatus Regenerative Technology has published its Q2 2025 quarterly earnings report on August 11, 2025.
Harvard Apparatus Regenerative Technology Quarterly report: Q1 2025
Harvard Apparatus Regenerative Technology has published its Q1 2025 quarterly earnings report on May 13, 2025.
Harvard Apparatus Regenerative Technology Proxy statement: Proxy Filing
Harvard Apparatus Regenerative Technology filed a proxy statement on April 29, 2025, providing details for shareholder voting and corporate governance matters.
Harvard Apparatus Regenerative Technology Proxy statement: Proxy Filing
Harvard Apparatus Regenerative Technology filed a proxy statement on April 17, 2025, providing details for shareholder voting and corporate governance matters.
Harvard Apparatus Regenerative Technology Annual report: Q4 2024
Harvard Apparatus Regenerative Technology has published its Q4 2024 annual report on March 30, 2025.
Harvard Apparatus Regenerative Technology Quarterly report: Q3 2024
Harvard Apparatus Regenerative Technology has published its Q3 2024 quarterly earnings report on November 13, 2024.
Harvard Apparatus Regenerative Technology Announces Strategic Collaboration with Children's Hospital Capital institute of Pediatrics in Beijing, China to Advance Treatment for Esophageal Atresia
Holliston, MA, Oct. 28, 2024 (GLOBE NEWSWIRE) -- Harvard Apparatus Regenerative Technology, Inc. (OTCQB: HRGN) (“Harvard Apparatus Regenerative Technology” or the “Company”), a clinical-stage biotechn...
Harvard Apparatus Regenerative Technology Appoints Mao Zhang to Board of Directors
Holliston, MA, Aug. 27, 2024 (GLOBE NEWSWIRE) -- Harvard Apparatus Regenerative Technology, Inc. (OTCQB: HRGN) (“Harvard Apparatus Regenerative Technology” or the “Company”), a clinical-stage biotechn...
Harvard Apparatus Regenerative Technology Announces $5 Million Financing to Continue Clinical Trial
Holliston, MA, Aug. 26, 2024 (GLOBE NEWSWIRE) -- Harvard Apparatus Regenerative Technology, Inc. (OTCQB: HRGN) (“Harvard Apparatus Regenerative Technology” or the “Company”), a clinical-stage biotechn...
Harvard Apparatus Regenerative Technology Quarterly report: Q2 2024
Harvard Apparatus Regenerative Technology has published its Q2 2024 quarterly earnings report on August 12, 2024.
Harvard Apparatus Regenerative Technology Reports First Quarter 2024 Financial Results and Recent Business Highlights
Holliston, MA, May 13, 2024 (GLOBE NEWSWIRE) -- Harvard Apparatus Regenerative Technology, Inc. (OTCQB: HRGN) (“Harvard Apparatus Regenerative Technology” or the “Company”), a clinical-stage biotechno...
Harvard Apparatus Regenerative Technology Quarterly report: Q1 2024
Harvard Apparatus Regenerative Technology has published its Q1 2024 quarterly earnings report on May 12, 2024.
Harvard Apparatus Regenerative Technology Earnings release: Q1 2024
Harvard Apparatus Regenerative Technology released its Q1 2024 earnings on May 12, 2024, summarizing the period's financial results.
Harvard Apparatus Regenerative Technology Proxy statement: Proxy Filing
Harvard Apparatus Regenerative Technology filed a proxy statement on April 29, 2024, providing details for shareholder voting and corporate governance matters.
Harvard Apparatus Regenerative Technology Reports Fourth Quarter and Full Year 2023 Financial Results and Recent Business Highlights
Holliston, MA, April 02, 2024 (GLOBE NEWSWIRE) -- Harvard Apparatus Regenerative Technology, Inc. (OTCQB: HRGN) (“Harvard Apparatus Regenerative Technology” or the “Company”), a clinical-stage biotech...
Harvard Apparatus Regenerative Technology Annual report: Q4 2023
Harvard Apparatus Regenerative Technology has published its Q4 2023 annual report on April 1, 2024.
Harvard Apparatus Regenerative Technology Earnings release: Q4 2023
Harvard Apparatus Regenerative Technology released its Q4 2023 earnings on April 1, 2024, summarizing the period's financial results.
Harvard Apparatus Regenerative Technology and the McGowan Institute for Regenerative Medicine at the University of Pittsburgh Establish a Research Collaboration to Study the Repair and Regeneration of the Colon following Colectomy
Holliston, MA, Dec. 18, 2023 (GLOBE NEWSWIRE) -- Harvard Apparatus Regenerative Technology, Inc. (OTCQB: HRGN) (“Harvard Apparatus Regenerative Technology” or the “Company”), a clinical-stage biotechn...